Lyra Therapeutics, Inc.
LYRA
$0.0873
$0.00080.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -49.07% | -58.05% | -66.56% | -15.52% | -13.39% |
| Total Depreciation and Amortization | 69.42% | -2.41% | -60.89% | -87.86% | -73.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 632.09% | 351.88% | 261.19% | -31.42% | -36.49% |
| Change in Net Operating Assets | -29.91% | -590.21% | -230.69% | -211.81% | -207.24% |
| Cash from Operations | -10.59% | -37.77% | -42.28% | -47.71% | -45.91% |
| Capital Expenditure | -123.30% | -1,005.21% | -1,793.64% | -2,616.38% | -538.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 816.33% | 170.85% | 149.97% | 88.41% | 82.21% |
| Cash from Investing | 738.15% | 166.34% | 144.38% | 83.15% | 80.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -87.28% | -43.99% | -43.98% | -22.23% | -31.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 92.06% | 81.63% | 67.95% | 9.92% | 13.94% |
| Cash from Financing | -87.01% | -41.31% | -42.37% | -22.78% | -31.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 284.61% | 99.47% | 67.05% | 47.34% | 15.96% |